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Endurance running is one of the most popular sports worldwide. [1,2] 
Increased participation can result in a higher risk of running-related 
injuries (RRIs), with the potential to increase analgesic use. [1,3] 
However, there is limited research investigating RRIs, or other 
factors, as possible predictors for analgesic use in runners.
Use and misuse of analgesics is prevalent and increasing in sporting 
populations, but this is not supported by adequate knowledge of the 
effects and adverse effects of these drugs.[4] Non-steroidal anti-
inflammatory drugs (NSAIDs) are one of the most common classes 
of analgesics used globally in the general population,[5,6] which may 
be attributed to high over-the-counter (OTC) accessibility.[7] Their 
significant risks of gastrointestinal, renal and cardiac adverse effects 
argue for appropriate knowledge prior to use, particularly during 
endurance exercise. Despite these risks, the rationales provided 
by athletes for analgesic use include perceptions of improved 
performance, and prophylactic management of injuries.[8] However, 
the lack of scientific evidence to support these proposed rationales for 
analgesic use[6] brings into question the sources of information that 
are influencing these athletes’ choices.
The apparent lack of knowledge regarding the safe use of analgesics, 
combined with OTC availability, potentially without professional 
input, is a major cause for concern.[8,9]
Objectives
To determine and describe practices regarding the use of analgesics in 
South Africa (SA)-based runners, focusing on the types of analgesics 
used, sources of information regarding analgesic use, and factors 
predicting use.
Methods
Ethical approval for the study was obtained from the Faculty 
of Health Sciences Human Research Ethics Committee (HREC), 
University of Cape Town (ref. no. 093/2016).
This study had a descriptive cross-sectional design.
Participants
Participants were recruited via online advertisements distributed to 
all SA running clubs listed on the Nedbank Runners Guide website 
(http://www.runnersguide.co.za) and through personal social media 
pages (Facebook and Twitter – @RThorpePhysio). Participants were 
included if they lived in SA, had internet access, were ≥18 years of 
age, considered running to be their main sport, and participated in 
at least one race, of indeterminate distance, per year. Participants 
were excluded if they did not provide informed consent or failed to 
complete the knowledge section of the survey.
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Background. The use of analgesics is prevalent in runners, with an associated potential for serious harm. More information is needed 
regarding runners’ practices and the factors that may influence their use of analgesics, to identify potential sources of misuse or abuse.
Objectives. To describe South Africa (SA)-based runners’ practices regarding use of analgesics, focusing on the types used, sources of 
information, and factors predicting use.
Methods. This study had a descriptive, cross-sectional design. SA-based runners aged ≥18 years, who had run at least one race during the 
year preceding the study, were included. Participants were recruited via social media and SA running clubs. They completed an online 
survey that included demographic information, training and competition history, and analgesic usage practices.
Results. Data from 332 participants (196 females, 136 males) were analysed. There was a high rate of analgesic use (64%), with 17% of users 
reporting concomitant use of more than one type of analgesic. The highest rate of analgesic use was after a run (80%). Non-steroidal anti-
inflammatory drugs (NSAIDs) were the most frequently used analgesics before (71%), during (50%) and after a run (74%). Importantly, 
NSAIDs and a combination NSAID-containing analgesic were the most common analgesics used concomitantly (19%). Most participants 
(90%) used over-the-counter analgesics, 41% of them receiving no input from any health professional. Sustaining a running-related injury 
increased the likelihood of analgesic use almost three-fold (Exp(B)=2.6; 95% confidence interval 1.59 - 2.41; p=0.0001).
Conclusions. A large percentage of runners in our study displayed unsafe practices regarding analgesic use during training and competition, 
predominantly for perceived injury management. Importantly, the lack of education and recommendations regarding analgesics from health 
professionals is very concerning, as there is a risk of potentially life-threatening analgesic-induced adverse effects, especially as a high 
percentage were using two NSAIDs concomitantly. Knowledge of these practices, gained through this study, could allow for the development 
and implementation of corrective strategies to promote education and safe practice of analgesic use in runners.
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Sample size determination
Sample size was calculated based on data from previous studies that 
determined prevalence rates of NSAID use in athletes.[8,10] Based 
on these studies,[8,10] the prevalence of NSAID use in athletes was 
between 56% and 75%. An expected prevalence of 60% was selected, 
and if the worst expected frequency was 50%, with confidence 
intervals (CIs) of 95%, the required sample size was 208 participants.
Measurement instrumentation: Questionnaire
A self-developed and validated questionnaire was used to investigate 
the participants’ practices regarding use of analgesics in running, as 
well as their training, competition and injury history.
The questionnaire consisted of four sections designed to 
address the main objectives of the study: (i) personal and medical 
information; (ii) training and race history, assessing preparation 
for, and performance in, training and competition; (iii) analgesic 
use, assessing participants’ running-related use of analgesics to 
determine whether practices regarding the use of analgesics were 
‘safe’ or ‘unsafe’ (in the questionnaire, analgesics were listed by their 
trade names, but for the interpretation of the results these have been 
combined into their generic names); and (iv) knowledge of and 
attitudes towards analgesics.
The questionnaire was submitted to a panel of three experts to 
be assessed for content and construct validity. The panel consisted 
of a sports physician, an exercise physiologist and a clinical 
pharmacologist, who were selected based on their experience and 
reputation in the field of clinical pharmacology and endurance 
sport. The questionnaire was submitted to the panel following 
ethical approval, with a request for their assistance in validating 
the questionnaire. The panel were requested to comment on the 
clarity, coherence and applicability of the questionnaire. The 
feedback from the panel was reviewed by the investigators, and 
appropriate modifications were made to the questionnaire. The 
final questionnaire was returned to the experts for consensus and 
approval, and was approved by the HREC.
Procedure
The final questionnaire was uploaded to the online survey website 
SurveyMonkey (www.surveymonkey.com). Participants were required 
to complete the informed consent process before gaining access to 
the questionnaire, and all participants were informed that responses 
were anonymous and IP addresses were not recorded. The survey 
was open for 1 month and was re-advertised after 3 weeks to remind 
participants of the study and to encourage completion of the survey.
It was the intention of the researchers to translate the questionnaire 
into Afrikaans, isiXhosa and isiZulu. However, owing to the rapidity 
of responses, the study was closed to further enrolment earlier 
than predicted, before the translation of the questionnaire could be 
completed.
Statistical analyses
Statistical analyses were performed using SPSS software (SPSS 
Statistics for Windows, version 23.0; IBM Corp., USA). A Shapiro-
Wilk test was used to determine whether the data were normally 
distributed. Frequency tables and Pearson’s χ2 measures of association 
were used for categorical variables, and an independent t-test was 
used for numerical variables. Odds ratios (ORs) and 95% CIs were 
calculated using VassarStats (http://www.vassarstats.net/odds2x2.
html) to determine associations between individual variables and 
analgesic use. Only variables that showed significant associations 
on multivariate testing were included in binary logistic regression 
models to determine whether any variables were predictive of 
analgesic use in runners. Regression model variables included the use 
of recovery methods and injury history.
Results
Participants
A total of 332 participants, 196 females (59%) and 136 males (41%), 
were included. This was significantly larger than the required sample, 
as there was an excellent response to the study, which resulted in data 
collection being completed >3 weeks ahead of schedule. There were 
no significant differences between male and female participants in 
age, level of education and employment history (Table 1).
Training and competition history
More than two-thirds of the participants (n=222; 67%) had been 
running for <10 years, the majority running <40 km a week (n=191; 
58%). Participants completed a mean (standard deviation) number 
of 3 (2) marathons and 2 (1) ultra-marathons during the year. 
More than half of the participants (n=185; 56%) used some form of 
recovery method after training or racing.
Injury history
More than half of the participants (n=173; 52%) reported an RRI 
within the 6 months prior to completing the questionnaire, with 
>20% of these participants suffering more than one RRI. Injury 
severity was separated into two groups: injuries that were severe 
enough to affect training or competition, and those that were not. 
Of the participants who suffered an RRI, 67% suffered injuries that 
affected running.
Running-related use of analgesics
Running-related use of analgesics was high (64%), with 17% of these 
participants using more than one analgesic concurrently.
Analgesics were predominantly used after a run (n=170; 80%), 
followed by during a run (n=119; 56%) and before a run (n=75; 35%). 
Of participants who reported use of analgesics, 29% used them after 
running, 24% used them during and after a run, and 17% used them 
before, during and after running.
Participants predominantly accessed OTC analgesics (n=190; 90%), 
41% with no healthcare practitioner recommendation. Pharmacists 
were only responsible for 25% of OTC recommendations, with 
friends and fellow runners (19%) the other main source of OTC 
recommendations.
NSAIDs were the most common class of analgesic used before 
(n=53; 71%), during (n=60; 50%) and after (n=126; 74%) a run, 
followed by combination analgesics and paracetamol (Table 2). 
Combination analgesics refers to analgesics that contain multiple 
medicines and include Myprodol (ibuprofen-paracetamol-codeine 
phosphate) and Spasmend (mephenesin-paracetamol). The anal-
gesic most commonly used before and after a run was the NSAID 
diclofenac, while Myprodol, the NSAID (i.e. ibuprofen combined 
with paracetamol-codeine phosphate) combination analgesic, was the 
most popular during a run and was used by 39% of runners (Table 3). 
Diclofenac and a combination analgesic, predominantly the NSAID 
(ibuprofen-paracetamol-codeine phos phate) combination, was the 
pairing most commonly used by participants who made use of 
more than one analgesic concurrently (19%). This was followed by 
the combination of diclofenac and paracetamol (16%). Paracetamol 
and a combination analgesic were used concurrently by 5% of 
participants.
The reasons for running-related analgesic use are set out in 
Table  4. Almost half of the participants who used more than one 
analgesic concomitantly gave the reason that ‘a single type of 
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analgesic was not effective in reducing joint or muscle pain’ (n=18; 
49%), while nearly a third did so ‘to aid in the recovery of a significant 
running injury’ (n=11; 30%).
Factors associated with running-related analgesic use
The odds of using analgesics was significantly higher in participants 
who reported a previous RRI (OR 2.68; 95% CI 1.69 - 4.26).
Multivariate analysis revealed no significant differences between 
any descriptive and sociodemographic factors in the running-related 
use of analgesics.
Regression analysis confirmed that having a previous RRI 
significantly predicted the use of analgesics by almost three-fold 
when controlling for other variables (Exp(B)=2.6; 95% CI 1.59 - 4.21; 
p=0.0001).
Discussion
Running-related use of analgesics
We found that 64% of participants reported running-related use of 
analgesics. The prevalence in our study is greater than the 25 - 60% 
prevalence of analgesic use previously reported in running and sports 
such as soccer and triathlons.[5,10-12] The concomitant use of more 
than one type of analgesic by 17% of participants in our study is 
comparable to recent research, where 10 - 32% of runners used more 
than one type of analgesic concurrently.[13]
Most participants in our study who used analgesics (90%) 
used OTC formulations, and only 25% did so on the advice of a 
pharmacist. However, we did not explore what advice was received 
from the pharmacist. Friends, family members and other runners 
(n=93; 49%) were common sources of information regarding 
analgesic use. A common reason cited for performance-enhancing 
drug use in athletes is known as the ‘false consensus effect’.[14] This 
effect results in an increase in drug use in athletes because they 
overestimate the prevalence of drug use in fellow athletes[14,15] and 
may explain why family, friends and fellow athletes can significantly 
influence the athlete’s attitudes and practice regarding drug use. [14] 
Although we were unable to substantiate the effect of these 
influences on the use of analgesics, we feel that they may play a 
similar role in runners.
Table 1. Sociodemographic characteristics and medical history of participants (N=332)
Characteristics Male (N=136) Female (N=196) Total (N=332) t p-value
Age (years), mean (SD) 39 (10) 38 (10) 38 (10) 1.24 0.22
Level of education, n (%) 7.48 0.38
Grade 7 or less 2 (2) 0 2 (1)
Completion of high school or equivalent (e.g. matric) 22 (16) 30 (15) 52 (16)
Diploma 32 (24) 40 (20) 72 (22)
Bachelor’s degree 29 (21) 47 (24) 76 (23)
Honours degree 26 (19) 46 (24) 72 (22)
Master’s degree 17 (13) 25 (13) 42 (13)
PhD 7 (5) 4 (2) 11 (3)
Other 1 (1) 4 (2) 5 (2)
Employment history (employed), n (%) 1.62 0.45
Yes 127 (93) 176 (90) 303 (91)
No 8 (6) 19 (10) 27 (8)
I prefer not to answer 1 (1) 1 (1) 2 (1)
Monthly income (ZAR), n (%) 37.79 0.001*
No income 9 (7) 20 (10) 29 (9)
1 000 - 4 999 0 3 (2) 3 (1)
5 000 - 9 999 5 (4) 22 (11) 27 (8)
10 000 - 19 999 21 (15) 61 (31) 82 (25)
20 000 - 30 000 31 (23) 41 (21) 72 (22)
>30 000 56 (41) 30 (15) 86 (26)
I prefer not to answer 14 (10) 19 (10) 33 (10)
SD = standard deviation.
*p<0.01. 
Table 2. Classes of analgesics used in running
Class
Time of use
Before a run (N=75), n (%) During a run (N=119), n (%) After a run (N=170), n (%)
NSAIDs 53 (71) 60 (50) 126 (74)
Combination analgesics 30 (40) 55 (46) 90 (53)
Paracetamol 26 (35) 43 (36) 57 (34)
Other 9 (12) 9 (8) 12 (7)
Muscle relaxant 5 (7) 9 (8) 9 (5) 
Cortisone 3 (4) 3 (3) 2 (1)
Codeine 0 3 (3) 7 (4)
NSAIDs = non-steroidal anti-inflammatory drugs.
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NSAIDs are regarded the first-line analgesic for the management of 
sports injuries.[5] In our study, they were found to be the commonest 
class of analgesic used before, during and after a run. Diclofenac was 
the most commonly used before and after a run, with Myprodol, 
the NSAID combination analgesic, used the most during a run. 
The use of Myprodol during running is of major concern, as it is a 
combination containing the NSAID ibuprofen, as well as paracetamol 
and codeine. It should be noted that diclofenac and Myprodol was 
the most common pairing of analgesics in our study. Their use in 
combination presents a major risk for additive NSAID toxicity, 
as runners are unknowingly combining the ibuprofen-containing 
Myprodol with another NSAID.
Similarly, there may be an increased risk of unintentional 
paracetamol overdose, as both combination analgesics used in our 
study, Myprodol and Spasmend, contain paracetamol. Paracetamol is 
a commonly used analgesic[16,17] and was the third most used class of 
analgesic in our study. It was paired with combination analgesics by 
5% of participants who used more than one analgesic concurrently. 
This practice is as concerning as the combined use of Myprodol 
with another NSAID, and while the adverse effects and risks may be 
different from those associated with excessive NSAID dosing, they 
are no less serious.
Paracetamol is popular because of its perceived safety and low risk of 
systemic adverse effects in therapeutic and low doses, up to 4 000 mg 
per day.[16-19] However, despite this perceived safety, paracetamol 
is a common cause of acute liver failure due to unintentional 
overdose,[17,18,20] as it can result in hepatotoxicity, hepatic necrosis 
and nephrotoxicity, which can be fatal.[17,18,21] In a multicentre US 
study in patients with an unintentional overdose, 63% were using 
acetaminophen (paracetamol)/opioid compounds.[22]
Toxicity is unusual from a single dose of paracetamol <150 mg/kg, 
or 7.5 - 10 g for an adult; however, it is likely to occur when >250 mg/
kg body weight or >12 g are consumed over a 24-hour period.[23-25] 
We note that if full daily doses of monocomponent paracetamol, i.e. 
4 000  mg, were added to the regulated dosages of the combination 
analgesics, there is a risk that a runner may inadvertently consume 
>7.5  g of paracetamol, and therefore be at risk of acute paracetamol 
toxicity.
Factors associated with running-related analgesic use
An RRI during the 6 months prior to the study predicted analgesic 
use in running, possibly because participants continued to run 
through injury to maintain fitness or to maintain participation. As 
a result, there is the potential for the injury to worsen as vulnerable 
Table 3. Types of analgesics used in running
Time of use
Type
Before a run (N=75), 
n (%)
During a run (N=119), 
n (%)
After a run (N=170), 
n (%)
NSAIDs
Aspirin 8 (11) 2 (2) 16 (9)
Diclofenac 40 (53) 36 (30) 106 (62)
Ibuprofen 15 (20) 21 (4) 44 (26)
Celecoxib 2 (3) 3 (3) 10 (6)
Other* 5 (7) 9 (8) 17 (10)
Combination analgesics
Ibuprofen-paracetamol-codeine phospate (Myprodol) 26 (35) 46 (39) 73 (43)
Mephensin-paracetamol (Spasmend) 7 (9) 15 (13) 29 (17)
Paracetamol
Paracetamol 21 (28) 30 (25) 51 (30)
Other* 6 (8) 14 (12) 9 (5)
Muscle relaxant
Diazepam 0 0 1 (1)
Other* 5 (7) 9 (8) 10 (6)
Corticosteroids
Corticosteroids 5 (7) 1 (1) 1 (1)
Other* 0 2 (2) 1 (1)
Codeine
Codeine 0 2 (2) 4 (2)
Other* 0 1 (1) 4 (2)
Other analgesics 9 (12) 9 (8) 12 (7)
NSAIDs = non-steroidal anti-inflammatory drugs.
*‘Other’ refers to additional analgesics that participants reported under each class/type of analgesic. These are separate to the class ‘Other analgesics’.




To alleviate headache 138 (59)
To reduce joint or muscle pain 111 (47)
Because of illness (flu, fever, nausea, etc.) 94 (40)
To aid recovery from a running injury 76 (33)
To decrease joint or muscle stiffness 50 (21)
To help with sleeping 24 (10)
To aid recovery after surgery 14 (6)
To reduce tiredness/fatigue 12 (5)
To prevent injury 6 (3)
Other 12 (5)
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tissues are overloaded with insufficient recovery time. There is 
also the risk that the use of analgesics, specifically NSAIDs, could 
delay the healing process, resulting in poor recovery and long-term 
injuries.[26] Long-term NSAID use can increase the risk of disordered 
healing in bones and tendons up to two-fold.[26] However, further 
research into these risks is required.[27] Runners need to be aware of 
how RRIs may be exacerbated by analgesic use.
Our participants were more likely to use analgesics after than 
before or during a run, which we assume was to manage pain, 
stiffness or injuries from the run, and to allow for enhanced 
recovery. [28-30] Most of our participants used analgesics to assist in the 
recovery of an RRI, despite there being no evidence to support their 
use in recovery.[31,32] The high use of analgesics, especially NSAIDs 
during and after a run, is concerning, as there is an increased risk 
of dehydration at this stage. [33] The use of NSAIDs in a dehydrated 
runner can result in acute renal failure.[34] It is evident that increased 
awareness of the serious risks of analgesic use after a run and in a 
dehydrated state is needed.
Despite the various regulatory restrictions surrounding analgesics, 
the most commonly used combination analgesic in our study, 
Myprodol, is schedule 3, requiring a doctor’s prescription. However, 
limited doses may be prescribed OTC under a pharmacist’s 
supervision as schedule 2, as the regulations allow for pharmacist 
initiation under certain circumstances.[35,36] These prescriptions 
and doses are recorded and closely monitored to prevent over-
purchasing and misuse of these analgesics. The OTC accessibility 
could be limiting the interaction between health professionals and 
the consumer.[37,38] It has been found that only small numbers of 
analgesic users are receiving professional medical recommendations 
regarding the appropriate use of analgesics.[39] The resulting lack of 
consultation regarding the effects and adverse effects is an urgent 
concern that needs to be addressed.
Recommendations
The ways in which runners are educated regarding analgesic use 
should be further investigated to determine the best means to address 
the high use and potentially unsafe practices. The roles of social 
media, running clubs and various media sources should be explored.
As OTC use is high, the role of the pharmacist in the provision 
of education and advice must be evaluated further. This role is 
important, as OTC NSAIDs and combination analgesics can only 
be accessed in a pharmacy. It should be noted that the combination 
analgesic Myprodol can be obtained via prescription or pharmacist 
initiation only, providing a further opportunity for pharmacists’ 
intervention.
Study limitations
We relied on self-reported data, which could not be independently 
verified. This may have biased the results due to recall.
The use of topical analgesics was not thoroughly investigated in 
our study. Topical analgesics, including NSAIDs, have been found to 
be as effective as some oral analgesics, with fewer adverse effects, and 
further investigation into topical analgesic use may be warranted.[40]
Conclusions
This study identified that there are large numbers of runners who 
are using analgesics during training and competition, and that in 
the majority of cases, practices were unsafe. A major concern is 
a lack of education and recommendations regarding analgesics 
from health professionals. Combined with the concomitant use of 
different analgesics, especially NSAIDs and paracetamol, this is very 
concerning, as it increases the risk of analgesic-induced adverse 
effects, which are potentially life-threatening.
It is essential for health professionals to provide improved 
education to runners regarding the safe use of analgesics, importantly 
the concomitant use of more than one NSAID. We believe that 
the scheduling and regulatory access of Myprodol in our country 
provides an important opportunity for healthcare professional 
intervention, which seems not to be occurring. Only via a concerted 
effort by runners, running club committees, competition organisers, 
social media and health professionals will the safe use of analgesics in 
running be inculcated in SA-based runners.
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